Semaglutide Benefits: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no outcome is presented as something a reader can expect. The frame throughout is what has been studied and what the study authors reported.

Semaglutide is a long-acting GLP-1 receptor agonist whose development history — including the structural modifications intended to extend its half-life relative to earlier GLP-1 analogues — was described in a 2019 review of the discovery and development of liraglutide and semaglutide (PMID 31031702). Because it has been examined in large randomised trials, the literature is unusually specific about which outcomes were measured and which were not.

How to read the evidence on this page

Study type matters more than headline direction. A randomised, double-blind, placebo-controlled phase 3 trial with a pre-specified primary endpoint supports a stronger inference than a secondary analysis or an exploratory measure. Several of the trials summarised below were large multi-year randomised trials; others were single-domain trials in narrowly selected populations. Where a paper reported a difference versus placebo, that is stated as a reported finding in that population, not as a general property of the molecule.

Body Weight: What Studies Report

Body weight is the most heavily studied outcome domain. A systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes pooled randomised trials and reported greater weight reduction with semaglutide than placebo (PMID 36578889).

Trials with behavioural or lifestyle backgrounds

The STEP 3 randomised clinical trial tested subcutaneous semaglutide against placebo as an adjunct to intensive behavioural therapy in adults with overweight or obesity and reported greater body weight reduction in the semaglutide group over the 68-week trial (PMID 33625476). The design point that researchers emphasised was that the comparison occurred on top of an already-intensive behavioural programme, so the placebo group also lost weight.

Maintenance versus withdrawal

Two papers speak directly to what happened when treatment continued or stopped. The STEP 4 randomised clinical trial randomised participants who had completed a run-in period to continued weekly subcutaneous semaglutide or placebo and reported that continued treatment was associated with further weight loss, whereas switching to placebo was associated with weight regain (PMID 33755728). Consistent with that, the STEP 1 trial extension followed participants after withdrawal of semaglutide and reported weight regain and reversal of cardiometabolic improvements toward baseline (PMID 35441470). Taken together, these two randomised datasets indicate that the reported weight effect was contingent on continued exposure rather than persisting after discontinuation (PMID 35441470, PMID 33755728).

Longer follow-up

The STEP 5 trial reported two-year effects of semaglutide in adults with overweight or obesity, extending the randomised comparison beyond the 68-week window used in most earlier trials (PMID 36216945). It is one of the few semaglutide weight trials with a two-year randomised horizon (PMID 36216945).

Higher dose investigation

The STEP UP trial was a randomised, controlled, phase 3b trial of once-weekly semaglutide 7·2 mg in adults with obesity (PMID 40961952). That trial examined whether a dose above those used in the earlier STEP programme changed the weight outcome and the adverse-event profile (PMID 40961952). No dose other than the one named in that paper is discussed here.

Cardiovascular Outcomes: What Studies Report

The SELECT programme was designed specifically to test cardiovascular events rather than weight. The rationale and design paper described SELECT as a trial of semaglutide effects on cardiovascular outcomes in people with overweight or obesity (PMID 32916609). The results publication reported that, among participants with obesity and pre-existing cardiovascular disease but without diabetes, semaglutide was associated with a lower incidence of cardiovascular events than placebo (PMID 37952131).

Two limits on interpretation follow from the trial's own population definition. First, the participants had established cardiovascular disease, so the reported event reduction cannot be generalised to people at low baseline risk (PMID 37952131). Second, the trial excluded diabetes, which is a different population from the earlier diabetes cardiovascular outcome literature (PMID 32916609).

Heart Failure With Preserved Ejection Fraction: What Studies Report

A 2025 JAMA paper examined semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction (PMID 40886075). This is a distinct clinical population from the obesity weight trials, and the HFpEF literature is best read as its own outcome domain rather than as an extension of weight findings (PMID 40886075).

Knee Osteoarthritis Pain: What Studies Report

One randomised trial addressed a musculoskeletal outcome directly. A 2024 New England Journal of Medicine trial of once-weekly semaglutide in persons with obesity and knee osteoarthritis reported greater reduction in knee pain scores with semaglutide than with placebo alongside weight reduction (PMID 39476339). The trial enrolled people who had both obesity and knee osteoarthritis, so it does not speak to joint pain in people without obesity (PMID 39476339).

Alcohol Use: What Studies Report

Interest in GLP-1 receptor agonists and addictive behaviours has largely been driven by observational reports and animal work. One randomised clinical trial of once-weekly semaglutide in adults with alcohol use disorder was published in 2025 and reported reductions in measures of alcohol consumption compared with placebo (PMID 39937469). Researchers framed that trial as an early randomised signal in a small, specifically selected population rather than a definitive result (PMID 39937469).

Outcome domains by study type

Claimed benefits with weak or absent evidence in this citation set

Several outcomes commonly attached to semaglutide in general discussion are not supported by the verified trials summarised on this page. Stating that plainly is part of reading the literature honestly.

• Longevity or anti-ageing. None of the cited trials measured lifespan or biological-ageing endpoints. Reported cardiovascular event reduction in a high-risk population (PMID 37952131) is not a longevity finding.
• Cognitive enhancement or neuroprotection. No cognitive endpoint appears in the trials cited here; the alcohol use disorder trial measured drinking behaviour, not cognition (PMID 39937469).
• Muscle building or body-composition improvement as a goal. The weight trials reported total body weight change rather than a favourable lean-mass outcome (PMID 36216945).
• Durable benefit after stopping. The STEP 1 extension reported the opposite pattern — weight regain and reversal of cardiometabolic changes after withdrawal (PMID 35441470).
• General joint pain relief. The only musculoskeletal trial cited here enrolled people with obesity and knee osteoarthritis specifically (PMID 39476339).

Adverse Events: What Studies Report

Every trial summarised above also reported safety data, and benefit discussions are incomplete without it. The systematic review and meta-analysis of semaglutide for weight loss in obesity without diabetes assessed safety alongside efficacy and reported gastrointestinal adverse events as the most frequent category (PMID 36578889). The STEP UP phase 3b trial of once-weekly semaglutide 7·2 mg likewise reported adverse events as part of its randomised comparison (PMID 40961952). Tolerability in randomised trials with structured monitoring and dose escalation is not necessarily the same as tolerability in unmonitored settings (PMID 40961952).

What the overall picture looks like

Across the verified literature, the pattern is a molecule with a well-characterised randomised evidence base in a narrow set of outcomes — body weight (PMID 36578889), cardiovascular events in people with obesity and established cardiovascular disease (PMID 37952131), and single trials in knee osteoarthritis (PMID 39476339) and alcohol use disorder (PMID 39937469) — with an explicit finding that reported effects diminished after withdrawal (PMID 35441470). Readers comparing sources should check which population a given trial enrolled and whether the outcome was primary or secondary before treating a reported difference as broadly applicable (PMID 32916609).

Approved semaglutide products exist in several jurisdictions for specified indications; approval status, labelling and any compounding rules differ by country and change over time, and this page does not attempt to summarise them. Again, this page is educational only and is not medical advice; decisions about any prescription medicine belong with a licensed physician.

References

• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design (American Heart Journal, 2020)
• Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial (JAMA, 2021)
• Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (JAMA, 2021)
• Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)
• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (Nature Medicine, 2022)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (New England Journal of Medicine, 2023)
• Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (New England Journal of Medicine, 2024)
• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (JAMA Psychiatry, 2025)
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)
• Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial (The Lancet Diabetes & Endocrinology, 2025)